JPMorgan Chase & Co. Reaffirms Overweight Rating for Spire Healthcare Group (LON:SPI)

Spire Healthcare Group (LON:SPI)‘s stock had its “overweight” rating reissued by analysts at JPMorgan Chase & Co. in a research note issued to investors on Thursday, Digital Look reports. They presently have a GBX 344 ($4.28) price target on the stock. JPMorgan Chase & Co.‘s price target would indicate a potential upside of 39.84% from the stock’s current price.

Separately, Berenberg Bank raised their target price on shares of Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the stock a “buy” rating in a report on Wednesday.

Spire Healthcare Group Stock Up 3.1 %

Shares of Spire Healthcare Group stock traded up GBX 7.50 ($0.09) during trading hours on Thursday, hitting GBX 246 ($3.06). 2,741,172 shares of the company’s stock traded hands, compared to its average volume of 446,274. The stock has a 50 day simple moving average of GBX 237.41 and a 200-day simple moving average of GBX 228.84. The company has a quick ratio of 0.74, a current ratio of 0.69 and a debt-to-equity ratio of 170.37. The company has a market cap of £994.16 million, a PE ratio of 3,514.29, a PEG ratio of 1.06 and a beta of 0.99. Spire Healthcare Group has a twelve month low of GBX 204 ($2.54) and a twelve month high of GBX 321.71 ($4.00).

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.